Vaccine Manufacturers Articles & Analysis: Older
27 news found
As they were passing by the R&D facilities, Bernard Sagaert, interim Chief Executive Officer of etherna, explained how the project is benefiting from etherna’s technologies, at multiple levels and stages: “We are delighted to partner with Univercells and Afrigen Biologics on this important project by providing expert support and knowhow in all the key areas of mRNA ...
ByeTheRNA
A common question of our clients is related to the size of a Cell Bank that is needed for future commercial manufacturing. How many vials of Master Cell Bank (MCB) and Working Cell Bank (WCB) do I need? ...
ByNuvonis
Viral vaccine manufacturing is a complex venture with the main steps being antigen production, purification and formulation. ...
ByNuvonis
An article presenting analyses of Continuous Glucose Monitoring (CGM) data from the randomised, placebo-controlled Phase 2b trial DIAGNODE-2 that assessed three intralymphatic injections of the therapeutic diabetes vaccine Diamyd®, has been published in the peer-reviewed scientific journal The Journal of Clinical Endocrinology & Metabolism (JCEM). ...
“There is growing evidence for the use of the therapeutic diabetes vaccine Diamyd also in prevention, says Ulf Hannelius, CEO of Diamyd Medical. The newly published results are exciting and we are looking forward to advancing our prevention efforts with the diabetes vaccine as part of the ambitious ASSET project alongside our partners. ...
The last patient in the investigator-initiated clinical trial DIAGNODE-B has received its additional injection (“booster”) of the therapeutic diabetes vaccine Diamyd®. The trial includes 6 patients with Type 1 diabetes who earlier participated in the DIAGNODE-1 or DIAGNODE-2 trials and who carry the genetic HLA DR3-DQ2 haplotype. ...
Updated 12-month results from the open-label investigator-initated Phase II clinical trial GADinLADA that assessed three intralymphatic injections of the therapeutic diabetes vaccine Diamyd® in individuals diagnosed with Latent Autoimmune Diabetes in Adults (LADA) were presented today at the European Association for the Study of Diabetes (EASD) conference in Stockholm, ...
An article presenting the 5-month interim results from the open-label trial GADinLADA that assessed three intralymphatic injections of the therapeutic diabetes vaccine Diamyd®, has been published in the peer-reviewed scientific journal Frontiers in Endocrinology. ...
“These results are very encouraging and the next step is together with collaborators and authorities evaluate the regulatory requirements to get the diabetes vaccine Diamyd approved as a disease-modifying therapy in individuals diagnosed with LADA”, says Ulf Hannelius, CEO of Diamyd Medical. ...
“Improvements in regulatory solutions achieved by the T1DC may ultimately lead to a faster and less recourse-demanding way to the market with direct relevance for planned and ongoing trials with the diabetes vaccine Diamyd.” “T1D poses a considerable burden to patients’ lives. ...
About DIAGNODE-3 The Phase III trial DIAGNODE-3, with the therapeutic vaccin Diamyd®, willl enroll approximately 330 individuals aged 12 to 28, recently diagnosed with type 1 diabetes, who carry the HLA DR3-DQ2 haplotype. ...
COVAXIN™ (BBV152) is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform. ...
The Company expects to commence manufacturing of ficlatuzumab clinical supply in the second quarter of 2022, subject to availability of key raw materials and manufacturing supplies also used in COVID-19 vaccine manufacturing, with the initiation of a registrational study now anticipated in the first half of 2023. ...
COVAXIN™ (BBV152) is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform. ...
COVAXIN™ is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform. ...
COVAXIN™ is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform. ...
While the accelerated development and scale-up of COVID-19 vaccines has shown what can be achieved by biopharmaceutical manufacturing, it has also highlighted the need to find ways to quickly and reliably develop and manufacture transformative drugs and therapies at scale. ...
Puretech’s AquaZero distillation system was recently supplied to Scotland based contract manufacturing organisation Andersen Caledonia. The system will enable the company to wash glass vials prior to sterile packing in its ISO 5 cleanroom. The vials will then be supplied to be filled with vaccines. The AquaZero Still generates Water for ...
Giebel as Chairman to support its novel vaccine platform through accelerated clinical development SpyBiotech has raised $32.5M from leading investors to advance development of its novel “plug and display” vaccine platform technology Braavos Investment Advisers led the round, joined by new investor Oxford Investment Consultants; founding investors ...
HBsAg VLPs are a licensed vaccine with excellent safety and immunogenicity data in humans and which are currently manufactured to billions of doses. ...